You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 18, 2025

Claims for Patent: 11,312,698

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,312,698

Title:	Fosnetupitant chloride hydrochloride having improved stability
Abstract:	Fosnetupitant chloride hydrochloride having improved stability, characterized by the following chemical structure:
Inventor(s):	Luca Fadini, Peter Manini, Claudio Pietra, Claudio Giuliano, Emanuela Lovati, Roberta Cannella, Alessio Venturini, Valentino J. Stella
Assignee:	Helsinn Healthcare SA
Application Number:	US16/896,135
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,312,698
Patent Claims:	1. Fosnetupitant chloride hydrochloride having the following formula: wherein the fosnetupitant chloride hydrochloride comprises less than 0.7% degradants via mass degradation under air and ambient conditions for a period of 80 days. 2. The fosnetupitant chloride hydrochloride of claim 1, wherein the degradants comprise netupitant. 3. A pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and fosnetupitant chloride hydrochloride having the following formula: wherein the fosnetupitant chloride hydrochloride comprises less than 0.7% degradants via mass degradation under air and ambient conditions for a period of 80 days. 4. The pharmaceutical composition of claim 3, wherein the degradants in the fosnetupitant chloride hydrochloride comprise netupitant. 5. An injectable pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and fosnetupitant chloride hydrochloride having the following formula: wherein the fosnetupitant chloride hydrochloride comprises less than 0.7% degradants via mass degradation under air and ambient conditions for a period of 80 days. 6. The injectable pharmaceutical composition of claim 5, wherein the degradants in the fosnetupitant chloride hydrochloride comprise netupitant. 7. Fosnetupitant chloride hydrochloride having the following formula: wherein the fosnetupitant chloride hydrochloride is in the form of an anhydrate; and wherein the fosnetupitant chloride hydrochloride comprises less than 0.7% degradants via mass degradation under air and ambient conditions for a period of 80 days. 8. The fosnetupitant chloride hydrochloride of claim 7, wherein the degradants comprise netupitant. 9. A pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and fosnetupitant chloride hydrochloride having the following formula: wherein the fosnetupitant chloride hydrochloride is in the form of an anhydrate; and wherein the fosnetupitant chloride hydrochloride comprises less than 0.7% degradants via mass degradation under air and ambient conditions for a period of 80 days. 10. The pharmaceutical composition of claim 9, wherein the degradants in the fosnetupitant chloride hydrochloride comprise netupitant. 11. An injectable pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and fosnetupitant chloride hydrochloride having the following formula: wherein the fosnetupitant chloride hydrochloride is in the form of an anhydrate; and wherein the fosnetupitant chloride hydrochloride comprises less than 0.7% degradants via mass degradation under air and ambient conditions for a period of 80 days. 12. The injectable pharmaceutical composition of claim 11, wherein the degradants in the fosnetupitant chloride hydrochloride comprise netupitant.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.